AbbVie Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (173)

Latest Posts

About This Stock More About This Stock
The 3 Highest-Yielding Dividend Aristocrats
Article By: Dividend Power
Tuesday, June 15, 2021 10:47 AM EDT
Despite the pandemic, the S&P 500 has nearly doubled off its bottom last year and is now trading at new all-time highs. Consequently, it has become hard for income investors to identify reasonably valued stocks with attractive dividends.
In this article: CVX, XOM, ABBV
The 3 Best Stocks To Buy Now That Yield Over 4%
Video By: Jason Fieber
Saturday, June 5, 2021 11:07 AM EDT
The S&P 500 – the benchmark equity representation of the US economy – is yielding less than 1.5%. Tough to live off of passive income with a yield like that.
In this video: O, VZ, ABBV
3 Dividend-Paying Pharmaceutical Stocks To Buy This Summer
Article By: StockNews
Saturday, June 5, 2021 7:00 AM EDT
The pharmaceutical industry has benefited from much investor attention amid the COVID-19 pandemic.
In this article: LLY, PFE, ABBV Also: IHE, PJP, MYOV
AbbVie (ABBV): An Undervalued Dividend Aristocrat
Article By: Dividend Diplomats
Tuesday, May 25, 2021 9:31 AM EDT
AbbVie Inc (ABBV) has an established eight-year track record of producing outstanding returns and superior dividend growth. Strong cash flow will enable ABBV to deleverage the balance sheet and support a growing dividend.
In this article: ABBV Also: ABT
A Quartet Of Aristocrats
Article By:
Sunday, May 23, 2021 11:56 AM EDT
If we assembled a group of blue-chip stocks for income investors, it would likely resemble the Dividend Aristocrats, which are S&P 500 Index stocks that have raised their dividends for at least 25 straight years.
In this article: AFL, MMM, PH, ABBV Also: ABT

Latest Tweets for $ABBV

No tweets yet!


5 Leading Healthcare Stocks Surging On Pent-up Demand
Craig Newman 11/11/2020 4:12:58 AM

Just a hunch. The healthcare industry is highly regulated and Dems generally favor more regulation, making it more difficult for drugmakers to secure the necessary regulatory approvals to market new products. Regulatory changes could drastically alter a healthcare stock’s growth prospects, for instance. But I reckon I'll not sell $ABBV after holding during all the long downward spiral.

5 Leading Healthcare Stocks Surging On Pent-up Demand
Craig Newman 11/10/2020 2:44:59 AM

Seems health stocks should do well but a #Biden presidency will not favor this sector. $ABBV $PFE

Macy’s Q1 Was Bad, But The Company Has The Cash To Survive The Current Pandemic
Jonathan Weber 7/3/2020 4:06:07 PM

Glad you liked it Sheryl! Right now I think a range of REITs and healthcare stocks are attractive from a risk-reward standpoint, including $ABBV, $BMY, $O, $SLG, $SPG, etc.

AbbVie: Is This Biopharma Giant’s 6% Yield Safe?
Beating Buffett 7/11/2019 1:00:14 PM

How much debt does $ABBV have?

AbbVie Has It All: Growth, Dividend Growth And Compelling Valuation
Dan Richards 6/25/2019 11:19:59 PM

$ABBV certainly sounds like a great buy.

AbbVie Inc. Increases Humira Prices, Receives FDA Approval For New Drug
Bruce Powers 1/23/2017 6:21:09 PM

Excited to hear the #FDA approved #IMBRUVICA. Should bode very well for $ABBV. And I think it's 8% price hike of #Humira is reasonable (though I realize those taking the drug may disagree).

1 to 6 of 6 comments